These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 338408)

  • 41. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
    N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pancreatic hormone secretion in chronic pancreatitis without residual beta-cell function.
    Larsen S; Hilsted J; Tronier B; Worning H
    Acta Endocrinol (Copenh); 1988 Jul; 118(3):357-64. PubMed ID: 2899369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early Alterations in Glycemic Control and Pancreatic Endocrine Function in Nondiabetic Patients With Chronic Pancreatitis.
    Lundberg R; Beilman GJ; Dunn TB; Pruett TL; Freeman ML; Ptacek PE; Berry KL; Robertson RP; Moran A; Bellin MD
    Pancreas; 2016 Apr; 45(4):565-71. PubMed ID: 26918872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. betacell function during insulin or chlorpropamide treatment of maturity-onset diabetes mellitus.
    Turner RC; Holman RR
    Diabetes; 1978; 27 Suppl 1():241-6. PubMed ID: 344115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function].
    Li X; Zhou ZG; Qi HY; Chen XY; Huang G
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Aug; 29(4):419-23. PubMed ID: 16134594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlates of insulin autoantibodies with beta cell function at the time of diagnosis of diabetes mellitus.
    al-Attas OS
    Am J Med Sci; 1995 Oct; 310(4):138-42. PubMed ID: 7573116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia.
    Vague P; Moulin JP
    Metabolism; 1982 Feb; 31(2):139-42. PubMed ID: 7043166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secretory B-cell activity in insulin dependent maturity-onset diabetic.
    Krause U; Faisst G; Cordes U; Beyer J
    Horm Metab Res; 1979 Apr; 11(4):261-5. PubMed ID: 378805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Importance of insulin absorption, subcutaneous blood flow, and residual beta-cell function in insulin therapy.
    Lauritzen T; Binder C; Faber OK
    Acta Paediatr Scand Suppl; 1980; 283():81-5. PubMed ID: 7010905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Free insulin, C-peptide and glucagon profiles in insulin dependent diabetes mellitus.
    Scott RS; Espiner EA; Donald RA; Ellis MJ
    Aust N Z J Med; 1980 Apr; 10(2):146-50. PubMed ID: 6992759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beta-cell function and metabolic control in insulin treated diabetics.
    Madsbad S; McNair P; Faber OK; Binder C; Christiansen C; Transbøl I
    Acta Endocrinol (Copenh); 1980 Feb; 93(2):196-200. PubMed ID: 6990673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers.
    Meier S; Hücking K; Ritzel R; Holst JJ; Schmiegel WH; Nauck MA
    Horm Metab Res; 2003 Sep; 35(9):551-6. PubMed ID: 14517773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function.
    Nyboe Andersen B; Krarup T; Thorsgaard Pedersen NT; Faber OK; Hagen C; Worning H
    Diabetologia; 1982 Aug; 23(2):86-9. PubMed ID: 6182047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum C peptide and IRI levels after administration of glucagon and glucose in non-insulin-dependent diabetics.
    Jayyab AK; Heding LG; Czyzyk A; Malczewski B; Królewski AS
    Horm Metab Res; 1982 Mar; 14(3):112-6. PubMed ID: 7040196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum magnesium in insulin-dependent diabetics and healthy subjects in relation to insulin secretion and glycemia during glucose-glucagon test.
    Menzel R; Pusch H; Ratzmann GW; Besch W; Förster F; Albrecht G; Ruhnke R
    Exp Clin Endocrinol; 1985 Feb; 85(1):81-8. PubMed ID: 3886415
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation. A comparison between insulin and C-peptide to measure insulin secretion.
    Gottsäter A; Landin-Olsson M; Fernlund P; Gullberg B; Lernmark A; Sundkvist G
    Scand J Clin Lab Invest; 1992 Nov; 52(7):631-9. PubMed ID: 1455155
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Residual beta-cell function and its metabolic consequences.
    Binder C; Faber OK
    Diabetes; 1978; 27 Suppl 1():226-9. PubMed ID: 344113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.